RDPAC药品推广行为准则 - IFPMA

研
制
开
发
制
药
企
业
协
会
都必须是合乎高道德标准、正当、
和专业的。会员公司不得支付或提
供任何可能向对方施加不当影响的
物品或服务。
10
4. 研发制药公司有责任提供
有关其产品的准确、平衡、和有科
学实证的信息。
5. 对药品的推广应当合乎高
道德标准的,准确和平衡的,且不
引起任何误解。推广材料中所记载
的药品信息应当包含对相关药品的
利益与风险的客观评价及正确的用
药方法。
6. 研发制药公司应尊重患者
的隐私与个人信息。
7. 所有由研发制药公司组织
或支持的临床试验和科学研究均
应以探索可使患者受益和科学与
医学进步的科学知识为其目的和
宗旨。研发制药公司致力于使行
业组织发起的患者临床试验越来
越透明、公开。
8. 研发制药公司应严格遵守
相关推广行为准则的条文及其内涵
的价值观。为此,研发制药公司应
确保其相关管理人员应接受充分的
培训。
all times be ethical, appropriate and
professional. Nothing should be offered
or provided by a company in a
manner or on conditions that would
have an inappropriate influence.
4. Pharmaceutical companies are
responsible for providing accurate,
balanced, and scientifically valid
data on products.
5. Promotion must be ethical, accurate,
balanced and must not be misleading.
Information in promotional
materials must support proper assessment
of the risks and benefits of
the product and its appropriate use.
6. Pharmaceutical Companies will
respect the privacy and personal information
of patients.
7. All clinical trials and scientific research
sponsored or supported by
companies will be conducted with
the intent to develop knowledge that
will benefit patients and advance
science and medicine. Pharmaceutical
companies are committed to the
transparency of industry sponsored
clinical trials in patients.
8. Pharmaceutical companies should
adhere to applicable industry codes
in both the spirit and the letter. To
achieve this, pharmaceutical companies
will ensure that all relevant
personnel are appropriately trained.